On May 28, 2026 PeproMene Bio, Inc. reported that updated clinical data from its ongoing Phase 1 study evaluating PMB-CT01, an investigational B-cell activating factor receptor (BAFF-R)-targeted CAR T-cell therapy, have been selected for an oral presentation at the 2026 Congress of the European Hematology Association (EHA) (Free EHA Whitepaper).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This presentation will highlight results from the completed dose-escalation portion of the study in relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL), including patients whose cancer has progressed following standard CD19-directed CAR T-cell therapy (NCT05370430).

Among the nine patients treated in this phase, PMB-CT01 demonstrated a promising safety profile with no dose-limiting toxicities, no grade >1 cytokine release syndrome (CRS), and no grade >1 immune effector cell-associated neurotoxicity syndrome (ICANS). Seven of nine patients (78%) achieved a complete response (CR). At the last data cutoff, no relapses had occurred and all responses remained ongoing, with the longest response exceeding 3 years. Responding patients also achieved minimal residual disease (MRD)-negative status, indicating deep remissions with no detectable residual cancer cells.

Building on these results, the trial is actively enrolling patients into expansion cohorts for mantle cell lymphoma, large B-cell lymphoma, and follicular lymphoma (FL). Importantly, the first patient treated in this expansion phase – a patient with transformed FL (tFL) who had progressed following CD19 CAR T therapy – achieved a CR at their first disease assessment. tFL is an aggressive form of lymphoma with limited established treatment options.

"When cancer progresses following CD19 CAR T therapy, patients face a significant unmet medical need, with very limited treatment options remaining," said Larry W. Kwak, M.D., Ph.D., scientific founder of PeproMene Bio. "These durable CRs clinically validate BAFF-R as a novel target, while the favorable safety profile observed to date may support future use in outpatient community oncology settings and further exploration in refractory autoimmune diseases."

Presentation Details

Abstract Title: Durable responses and favorable safety of BAFF-R CAR T-cells (PMB-CT01) in patients with relapsed/refractory B-cell lymphomas with prior CD19-directed therapy failure or CD19-negative disease

Abstract: EHA (Free EHA Whitepaper)-1611 S287

Date/Time: June 14, 11:00 AM – 12:15 AM CEST

Presenter: Larry W. Kwak, M.D., Ph.D.

About PMB-CT01

PMB-CT01 is a first-in-class BAFF-R-targeted autologous CAR T-cell therapy being evaluated in ongoing Phase 1 trials for relapsed/refractory B-NHL and relapsed/refractory B-ALL. BAFF-R is expressed almost exclusively on B cells and is essential for B-cell survival, reducing the likelihood of antigen-loss escape.

(Press release, PeproMene Bio, MAY 28, 2026, View Source [SID1234666165])

On May 28, 2026 Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, reported that the Company will participate in the following investor events during the month of June.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details are as follows:

Jefferies Global Healthcare Conference
Date: Thursday, June 4, 2026
Time: 8:45 AM ET
Webcast Link: View Source

Goldman Sachs 47th Annual Global Healthcare Conference
Date: Tuesday, June 9, 2026
Time: 8:00 AM ET
Webcast Link: View Source

Virtual/Replay availability: Presentations will be archived on Compass’ Events page.

Compass’ management will be available for one-on-one meetings during all events. Interested investors should contact their respective representatives to request meetings.

(Press release, Compass Therapeutics, MAY 28, 2026, View Source [SID1234666181])

On May 28, 2026 NETRIS Pharma, a clinical-stage oncology company targeting the netrin-1 / epithelial-to-mesenchymal transition (EMT) axis, reported that it has secured €7.25 million in funding under the European Union’s Horizon Europe programme to conduct a Phase 2b randomized clinical trial of NP137 in head and neck squamous cell carcinoma (HNSCC). The trial will be led by Principal Investigator Dr. Jérôme Fayette, MD, PhD, a medical oncologist at Centre Léon Bérard (Lyon, France), and conducted in partnership with GORTEC (Groupe Oncologie Radiothérapie Tête Et Cou), the leading French cooperative oncology group in HNSCC led by Professor Jean Bourhis and TTCC group, the Spanish group for the treatment of head and neck tumors, chaired by Dr. Ricard Mesia.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

« Head and neck squamous cell carcinoma remains a disease with significant unmet need, particularly with a large portion of patients relapsing under immunotherapy. The scientific rationale for targeting netrin-1 in HNSCC to alleviate resistance to immunotherapy and thus extend the survival of patients is compelling,and the clinical outcomes from the Phase2 ImmunoNET study confirms the potential of NP137 to deliver meaningful clinical benefit for our patients » said Dr. Jérôme Fayette, MD, PhD, Principal Investigator and Medical Oncologist at Centre Léon Bérard.

Patrick Mehlen, PhD, Chief Executive Officer of NETRIS Pharma, said: « We are delighted to receive this Horizon Europe grant, which is a further validation of both our scientific approach and our development strategy in head and neck cancer. NP137 is the only clinical-stage anti-netrin1 therapy, and HNSCC is a key indications given the resistance to current treatment. Conducting this Phase 2b study in partnership with GORTEC, the most experienced cooperative group in this field, and under the leadership of Dr. Fayette, provides the ideal framework to generate the high-quality clinical evidence needed to advance NP137 toward regulatory discussions. This funding reinforces our commitment to bringing truly differentiated therapies to patients with limited options ».

« GORTEC is proud to partner with NETRIS Pharma on this innovative Phase 2b programme. Head and neck cancer is a field where new mechanistic approaches are urgently needed. The netrin-1 / EMT axis represents a clinically actionable target, and we look forward to generating robust data in the context of this well-designed Horizon Europe-funded trial » said Professor Jean Bourhis, Chief Executive Officer and Chief Medical Officer of GORTEC.

The Horizon Europe programme is the European Union’s key funding mechanism for research and innovation. « Following the positive outcome of the immunonet study, this funding reflects the high value of NP137 in oncology », said Christophe Guichard, Chief Financial Officer of NETRIS Pharma. The funding will support the design, conduct and analysis of the Phase 2b randomized trial in HNSCC, building on the clinical evidence supporting the role of netrin-1 in driving treatment resistance in this indication. The project will be conducted through a consortium led by NETRIS Pharma with GORTEC, Grupo Español de Tratamiento de Tumores de Cabeza y Cuello – TTCC and Université Libre de Bruxelles.

About the Phase 2b HNSCC Trial

The Phase 2b trial is a randomized, multi-center study evaluating NP137 in patients with head and neck squamous cell carcinoma. The study will be conducted across multiple centers in France and Spain under the sponsorship of GORTEC, with Dr. Jérôme Fayette of Centre Léon Bérard serving as Principal Investigator. The trial design will incorporate translational endpoints aimed at further characterizing the role of netrin-1 and its receptors as predictive biomarkers of response to NP137, consistent with NETRIS Pharma’s precision oncology development strategy.

Full details of the trial design, including patient population, primary and secondary endpoints, and treatment schedule, will be disclosed at the time of trial initiation.

About Head and Neck Squamous Cell Carcinoma (HNSCC)

Head and neck squamous cell carcinoma (HNSCC) encompasses cancers of the oral cavity, pharynx, larynx, and other structures of the upper aerodigestive tract. It represents the sixth most common cancer worldwide, with approximately 900,000 new cases and 450,000 deaths annually. Despite advances in surgery, radiotherapy, and systemic therapy including checkpoint inhibitor immunotherapy, outcomes for patients with recurrent and/or metastatic HNSCC remain poor, with median overall survival of approximately 14–15 months with current standard-of-care regimens.

NETRIS Pharma has established a scientific rationale for netrin-1 blockade in HNSCC based on the role of netrin-1 in driving epithelial-to-mesenchymal transition (EMT) and acquired resistance to treatment, mechanisms that are highly relevant in this tumor type. NP137 is currently in clinical development in HNSCC as part of NETRIS Pharma’s broader multi-indication development strategy.

About GORTEC

GORTEC (Groupe Oncologie Radiothérapie Tête Et Cou) is the leading French cooperative oncology group dedicated to the clinical development of innovative treatments for head and neck cancers. GORTEC has conducted numerous landmark clinical trials in HNSCC and is widely recognized as one of the most prolific and scientifically rigorous cooperative groups in this field in Europe. The group is led by Professor Jean Bourhis, a world-leading expert in head and neck oncology and radiation oncology.

(Press release, Netris Pharma, MAY 28, 2026, View Source [SID1234666150])

On May 28, 2026 Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) reported that the Phase II clinical study of its proprietary PD-L1/4-1BB bispecific antibody, Opamtistomig (LBL-024), in combination with chemotherapy for the first-line treatment of non-small cell lung cancer (NSCLC), has been selected for an oral presentation at the 2026 World Conference on Lung Cancer (WCLC), the world’s most influential scientific meeting in the lung cancer field, taking place September 12–15, where Leads Biolabs will present breakthrough efficacy data based on an expanded patient cohort compared to the previously reported 18-patient dataset.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Previously reported early-stage NSCLC data showed that Opamtistomig combined with chemotherapy achieved a compelling objective response rate (ORR). With extended follow-up, deepening tumor responses and durable tumor shrinkage were observed across multiple subgroups, including immunotherapy-pretreated non-squamous NSCLC, first-line non-squamous NSCLC, and first-line squamous NSCLC.

At WCLC 2026, the Company will present updated data demonstrating high response rates and continuously deepening tumor shrinkage of Opamtistomig in an expanded patient population, along with a safety profile consistent with previous findings. These results further validate the safety breakthrough enabled by conditional 4-1BB activation via the X-body platform and highlight Opamtistomig’s differentiated clinical advantages in first-line NSCLC.

Opamtistomig’s potential as an IO 2.0 pan-tumor backbone therapy is being validated in three key dimensions—broad antitumor activity, long-term survival benefit trends, and a safety profile comparable to PD-(L)1 inhibitors: its clinical development spans 13 solid tumor indications, demonstrating first- or best-in-class potential in multiple tumor types, including NSCLC, extrapulmonary neuroendocrine carcinoma (EP-NEC), small cell lung cancer (SCLC), and biliary tract cancer (BTC); clear survival benefit trends have been observed in multiple indications, with potential to translate into long-term efficacy benefits with continued follow-up; and with over 600 patients enrolled, Opamtistomig demonstrated a favorable safety profile as monotherapy and in combination with chemotherapy, with no dose-limiting toxicities observed and the maximum tolerated dose not reached at doses up to 25.0 mg/kg.

Executive Commentary
Dr. Charles Cai, Chief Medical Officer of Leads Biolabs, stated: "The selection for an oral presentation at WCLC represents strong recognition from the international academic community of Opamtistomig’s innovative mechanism and clinical value, and further validates its breakthrough therapeutic potential in first-line NSCLC. As we accumulate data from larger patient cohorts and longer follow-up, we continue to observe significant trends toward deeper and more durable responses across broader patient populations. We look forward to sharing these important findings with global experts at WCLC and continuing to advance Opamtistomig toward becoming a new backbone of cancer immunotherapy worldwide."

About Opamtistomig
Opamtistomig (LBL-024) is emerging as a next-generation pan-cancer backbone therapy with potential overall survival (OS) benefit that simultaneously targets PD-L1 and the co-stimulatory receptor 4-1BB. Developed using Leads Biolabs’ proprietary X-Body bispecific platform, Opamtistomig is designed to simultaneously block PD-1/L1 immune suppression and conditionally activate 4-1BB, an agonist pathway, resulting in a potent and synergistic anti-tumor immune response. It has a safety profile comparable to PD-1/PD-L1 inhibitors and demonstrates broader-spectrum anti-cancer potential. To date, Opamtistomig has demonstrated first- or best-in-class potential in Phase II or registrational clinical trials across four indications: non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), biliary tract cancer (BTC), and extrapulmonary neuroendocrine carcinoma (EP-NEC).

As the first 4-1BB–targeting bispecific antibody globally to advance to a single-arm pivotal trial as monotherapy, Opamtistomig has been evaluated in 13 solid tumor indications in China, including 1 pivotal registration trial and 8 proof-of-concept studies. These cover EP-NEC, NSCLC, SCLC, BTC, ovarian cancer (OC), esophageal squamous cell carcinoma (ESCC), hepatocellular carcinoma (HCC), gastric cancer (GC), triple-negative breast cancer (TNBC), malignant melanoma, and other areas with high unmet medical needs.

Mechanistically, 4-1BB agonism can reactivate exhausted T cells and promote robust T-cell proliferation, offering significant promise for PD-1/PD-L1–resistant or immunologically "cold" tumors. Recognizing its clinical potential, Opamtistomig received Breakthrough Therapy Designation (BTD) from China’s National Medical Products Administration (NMPA) in October 2024, and Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for the treatment of neuroendocrine carcinoma in November 2024. Additionally, in January 2026, Opamtistomig was granted Fast Track Designation (FTD) by the FDA and ODD by the European Commission for the treatment of EP-NEC, further underscoring its potential to address unmet medical needs in this patient population.

(Press release, Nanjing Leads Biolabs, MAY 28, 2026, View Source [SID1234666166])

On May 28, 2026 BPGbio, Inc., a clinical-stage biopharmaceutical company advancing mitochondrial-targeted therapeutics for patients, reported that new clinical progress from its ongoing Phase 2 study of BPM31510 in newly diagnosed glioblastoma multiforme (GBM) will be presented at the upcoming ASCO (Free ASCO Whitepaper) Annual Meeting.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The trial-in-progress poster will be presented by Seema Nagpal, M.D., Principal Investigator of the study and Professor of Neurology and Neurological Sciences at Stanford Medicine.

Abstract Details

Abstract Number: TPS2101
Title: Progress report of a phase 2 study of BPM31510 (a lipid nano dispersion of oxidized CoQ10) with vitamin K in combination with standard of care (SOC) RT and TMZ in glioblastoma multiforme (GBM) patients without prior therapy
Session Type/Title: Poster Session – Central Nervous System Tumors
Poster Board: 461b
Presentation Date & Time: Monday, June 1, 2026 | 1:30 PM – 4:30 PM CDT

The ongoing Phase 2 study is evaluating BPM31510, an investigational lipid nanodispersion formulation of oxidized Coenzyme Q10 (CoQ10), administered with vitamin K1 in combination with standard-of-care radiation therapy (RT) and temozolomide (TMZ) in patients with newly diagnosed GBM who have not received prior therapy.

BPM31510 is designed to target dysregulated mitochondrial metabolism in cancer cells. By modulating mitochondrial function and restoring oxidative balance, BPM31510 aims to induce tumor-selective redox stress while helping preserve healthy tissue metabolism. The investigational therapy seeks to re-engage mitochondrial pathways that may contribute to tumor cell vulnerability in highly aggressive cancers such as glioblastoma. Moreover, the direct targeting of the BCL-2 protein family serves to sensitize patients to radiotherapy.

"The BPM31510 phase I trial delivered pharmacodynamic proof, PET-confirmed reversal of the Warburg effect, shifting tumor metabolism from glycolysis to oxidative phosphorylation at supraphysiologic CoQ10 concentrations. That metabolic reprogramming drives a ROS-mediated, BCL-2–dependent apoptotic cascade that may finally unlock glioblastoma’s mitochondrial vulnerability", said Vivek Subbiah, M.D., Jeffrey and Christina Bird Endowed Chair and Professor of Medicine, Division of Oncology and Associate Director for Drug Development and Precision Oncology at the Stanford Cancer Institute, Stanford University School of Medicine, CA, USA. "For patients with GBM, a devastating disease where median survival remains under two years despite decades of research, the ongoing front-line study is a test of whether this science can translate into a meaningful survival benefit."

Glioblastoma is the most common and aggressive malignant primary brain tumor in adults and is associated with poor survival despite multimodal treatment approaches. Increasing evidence suggests that altered mitochondrial metabolism plays a critical role in glioblastoma progression, treatment resistance, and tumor adaptation.

The ongoing Phase 2 study builds upon prior clinical and translational research evaluating BPM31510 across oncology indications and reflects BPGbio’s broader focus on targeting mitochondrial dysfunction in diseases with significant unmet medical need.

"Glioblastoma remains one of the most devastating cancers, with limited therapeutic advances for patients in recent decades," said Niven R. Narain, Ph.D, President and Chief Executive Officer of BPGbio. "We believe mitochondrial targeting represent an important and underexplored therapeutic frontier in GBM in oncology. BPM31510 is designed to target the mitochondrial metabolism that cancer cells depend upon, increasing OXPHOS and ROS, restoring apoptotic potential to a cancer cell. The emerging data in this study is encouraging, and we look forward to sharing updates with the community at ASCO (Free ASCO Whitepaper)."

About BPM31510
BPM31510 is an investigational first-in-class mitochondrial therapeutic consisting of a lipid nano dispersion formulation of oxidized CoQ10 designed to modulate mitochondrial metabolism. BPM31510 is being evaluated across oncology and rare disease indications, including glioblastoma multiforme (GBM), pancreatic cancer, and Primary CoQ10 Deficiency (PCQD). BPM31510 has received Orphan Drug Designation and Pediatric Rare Disease Designation from the U.S. Food and Drug Administration for multiple indications.

(Press release, BPGbio, MAY 28, 2026, View Source [SID1234666182])